Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Fineline Cube Apr 1, 2026
Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Fineline Cube Apr 1, 2026
Company

UIH Surgical to Invest RMB 2.5 Billion in Wuhan Medical Innovation and Robotics Base

Fineline Cube Jun 14, 2023

United Imaging Healthcare Technology Co., Ltd (UIH), through its subsidiary UIH Surgical, has announced plans...

Company Deals Medical Device

JJET’s IPO on STAR Market Accepted, Aims to Raise RMB 2.691 Billion for Medical Device Expansion

Fineline Cube Jun 14, 2023

China-based JJET has received acceptance for its Initial Public Offering (IPO) filing on the Shanghai...

Company Drug

Genevector Initiates Clinical Study for JWK001 in Neovascular Age-Related Macular Degeneration

Fineline Cube Jun 14, 2023

Chengdu-based adeno-associated virus (AAV) gene therapy developer, Genevector Biotechnology Co., Ltd., has announced the first...

Company Drug

Convalife Pharmaceuticals Gets NMPA Approval for Generic Neratinib Clinical Study

Fineline Cube Jun 14, 2023

Shanghai-based Convalife Pharmaceuticals has announced that it has received approval from the National Medical Products...

Company Drug

Croma-Pharma Initiates Phase III Clinical Trial in China for Hyaluronic Acid Dermal Filler

Fineline Cube Jun 13, 2023

Austria-based Croma-Pharma has revealed that the first patient is set to be enrolled in a...

Company Deals R&D

Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research

Fineline Cube Jun 13, 2023

Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement...

Company Deals

Apeloa Pharmaceutical Partners with Zelgen Biopharmaceuticals for CDMO Programs

Fineline Cube Jun 13, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Drug

Sinocelltech Group Receives NMPA Approval for Biosimilar Version of Humira

Fineline Cube Jun 13, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received market approval from...

Company Drug

Bio-Thera Solutions’ BAT6026 Receives NMPA Approval for Atopic Dermatitis Clinical Trials

Fineline Cube Jun 13, 2023

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced receiving approval from China’s National Medical Products...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Gets EU Approval for Global Phase III Study

Fineline Cube Jun 13, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving the green light from EU...

Company Drug

CSPC Pharmaceutical Gets NMPA Approval for ATM Inhibitor SYH2051 Clinical Study

Fineline Cube Jun 13, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Deals

VIVA Biotech Holdings Divests Stake in Shanghai Unit to Temasek-Backed Entities

Fineline Cube Jun 13, 2023

China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has agreed to sell a...

Company Drug

China Medical System’s Diazepam Nasal Spray Receives NMPA Approval for Cluster Seizures

Fineline Cube Jun 13, 2023

China-based China Medical System Holdings Ltd (CMS; HKG: 0867) has announced receiving New Drug Application...

Company Drug

Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ICML

Fineline Cube Jun 13, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...

Company Drug

AstraZeneca’s Soliris Secures Third Indication for Myasthenia Gravis in China

Fineline Cube Jun 13, 2023

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that its Soliris (eculizumab), a first-in-class...

Company Drug

Abbisko Therapeutics Initiates Phase II Study for Pimicotinib in Chronic Graft-Versus-Host Disease

Fineline Cube Jun 12, 2023

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing...

Policy / Regulatory

NHSA Launches 2023 NRDL Update Process with New Work Plan and Public Feedback Period

Fineline Cube Jun 12, 2023

The National Healthcare Security Administration (NHSA) has commenced the process for the annual update of...

Company Drug

Genor Biopharma’s Geptanolimab NDA for PTCL Rejected by China’s NMPA

Fineline Cube Jun 12, 2023

China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced that the National Medical Products Administration...

Company Drug

CSPC Pharmaceutical’s CPO301 Earns Fast-Track Status for EGFR Mutant NSCLC Treatment

Fineline Cube Jun 12, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...

Company Drug

Salubris Pharmaceuticals’ Enarodustat Gains NMPA Approval for Renal Anemia Treatment

Fineline Cube Jun 12, 2023

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving market approval from the...

Posts pagination

1 … 494 495 496 … 645

Recent updates

  • Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
  • Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
  • Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
  • Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
  • Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Company Drug

Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.